1. A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). (1st May 2019) Authors: Corrie, P.G.; Terheyden, P.; ten Tije, A.J.; Herbst, R.; Jansen, R.; Marples, M.; Debus, D.; Marconcini, R.; Blasinska‐Morawiec, M.; Freivogel, K.; Munson, M.L.G.; Goodman, G.R.; Hsu, J.J.; Sadetsky, N.; Colburn, D.; Rutkowski, P. Journal: British journal of dermatology Issue: Volume 180:Number 5(2019) Page Start: 1254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). (10th February 2019) Authors: Corrie, P.G.; Terheyden, P.; ten Tije, A.J.; Herbst, R.; Jansen, R.; Marples, M.; Debus, D.; Marconcini, R.; Blasinska‐Morawiec, M.; Freivogel, K.; Munson, M.L.G.; Goodman, G.R.; Hsu, J.J.; Sadetsky, N.; Colburn, D.; Rutkowski, P. Journal: British journal of dermatology Issue: Volume 180:Number 5(2019) Page Start: 1254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗